bazedoxifene acetate; estrogens, conjugated · Wyeth Pharms · NDA 022247
Duavee
Earliest generic entry, as listed
10 Mar 2027
Blocked by patent: US 7683051.
Listed patents · 1 unexpired
2 Orange Book listing rows for 1 patent. FDA lists a patent once for each use code, and lists its pediatric extension as a separate row.
| Patent | Claims | Expires |
|---|---|---|
| US 7683051 | drug substance, drug product, use U-594, U-904 | 10 Mar 2027 |
| US 7683051 listing row | drug substance, drug product, use U-594 · sets the listed date | 10 Mar 2027 |
| US 7683051 listing row | drug substance, drug product, use U-904 · sets the listed date | 10 Mar 2027 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
- Enters 12-month window basis: patent · 022247-001Listed date 10 Mar 2027Detected 24 Oct 2026
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 022247 · 001 · RLD | tablet, oral | EQ 20MG BASE;0.45MG | 10 Mar 2027 |